As our priority area of research, we are committed to propelling drug discovery in oncology. To help spark meaningful research in this space, the Global Oncology External Innovation Hub enhances collaboration with those who share our joint pursuit to fight cancer with purposeful science.
The Global Oncology External Innovation Hub, led by Mahmoud Mahmoudian, Ph.D., F.R.S.C., is an integral part of our research partnerships to advance the discovery of novel therapeutics and is a key component of our Global Oncology Research.
“Innovation is at the core of everything that we do, and the establishment of the Global Oncology External Innovation Hub exemplifies our commitment to oncology and drug discovery. It is our vision that our external innovation efforts will help us grow our understanding of cancer as a disease and, most importantly, lead to the identification of new treatments for patients with cancer.”
—Dr. Mahmoud Mahmoudian, F.R.S.C., Senior Vice President, Head of Global Oncology External Innovation
In December 2019, we entered into an alliance with three world-leading oncology centers of excellence—Columbia University, Harvard University, and the Wistar Institute. Through this alliance, we are supporting research endeavors dedicated to finding novel targets and platform technologies for the development of cancer drugs.
By leveraging each institution’s unique technologies and therapeutic insights to pursue specific research areas, we believe this partnership will bring us closer to filling unmet needs in oncology.
In March 2020, Sumitomo Dainippon Pharma invested in the MPM Oncology Innovations Fund and made a donation to the Dana-Farber Innovations Research Fund. These two funds are unique, impact-investing collaborations that combine fundraising for biotech venture capital investing with philanthropic fundraising for cancer research.
By harnessing MPM Capital’s expertise in establishing and investing in life science companies, we believe this effort will enable efficiencies in the drug discovery process and the use of cutting-edge technologies in oncology.